Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Yentreve/Ariclaim (duloxetine) will be the dominant treatment in Europe for stress urinary incontinence and will drive the growth of the indication's market to $378 million in 2013.

According to the new Pharmacor study, Stress Urinary Incontinence, the launches of novel drug therapies-including Yentreve/Ariclaim-will dramatically increase the drug-treated population for the illness to 1.8 million by 2013. Although Eli Lilly/Boehringer Ingelheim's Yentreve/Ariclaim entered the European market in 2004 and is forecasted to gain a 90% share in that region, the drug's uncertain future in the United States could greatly restrict its commercial potential.

"In January 2005, Eli Lilly and Boehringer Ingelheim withdrew duloxetine's new drug application for the treatment of stress urinary incontinence in the United States after the FDA reported it could not approve the agent based on the data submitted," said Kat Lynch, analyst at Decision Resources. "Without a presence in the United States -- the largest regional market for virtually all pharmacotherapies -- duloxetine is faced with greatly restricted commercial potential."

Before 2004, the therapy market for stress urinary incontinence was dominated by surgical treatment and other nonpharmacological approaches. Following European approval of the serotonin and norepinephrine reuptake inhibitor (SNRI) duloxetine, the first pharmacological therapy indicated for stress urinary incontinence, manufacturers are hoping to capitalize on this newly defined market with the development of additional SNRI treatments.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

HMO Enrollment Down in Several New England States

View Now